IPI-549 is a selective inhibitor of phosphoinositide 3-kinase gamma (PI3Kγ), a key enzyme involved in immune cell signaling. Its primary application lies in cancer immunotherapy, where it modulates the tumor microenvironment by reprogramming immunosuppressive myeloid cells into immune-stimulating phenotypes. This shift enhances T-cell activation and improves the body’s anti-tumor immune response. IPI-549 has been investigated in clinical trials, often in combination with checkpoint inhibitors like anti-PD-1 therapies, to boost their effectiveness in solid tumors. It shows potential in treating cancers where PI3Kγ activity contributes to immune evasion, including melanoma, non-small cell lung cancer, and other advanced solid tumors. Additionally, its role in reducing tumor-associated macrophage suppression supports ongoing research in combination therapies aimed at overcoming resistance to current immunotherapies.